[Hydroxychloroquine for non-severe extra-pulmonary sarcoidosis].
L’hydroxychloroquine pour la sarcoïdose extra-pulmonaire non-sévère.
Corticosteroids
Corticoïdes
Hydroxychloroquine
Sarcoidosis
Sarcoïdose
Journal
La Revue de medecine interne
ISSN: 1768-3122
Titre abrégé: Rev Med Interne
Pays: France
ID NLM: 8101383
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
09
07
2021
revised:
11
03
2022
accepted:
21
04
2022
pubmed:
7
6
2022
medline:
14
7
2022
entrez:
6
6
2022
Statut:
ppublish
Résumé
Sarcoidosis can develop into a chronic disease in about 30% of cases. When general treatment is indicated, corticosteroids are the first-line treatment. More than one third of patients treated with corticosteroids receive a steroid-sparing agent. Although methotrexate is the most commonly used sparing agent, synthetic antimalarials have been used for more than fifty years on the basis of small, randomised, therapeutic trials. Despite this low level of evidence, chloroquine or more often hydroxychloroquine are used in daily practice, particularly to treat skin, bone and joint sarcoidosis, as well as hypercalcemia and certain types of uveitis. This review summarises the state of knowledge on steroid-sparing therapy in sarcoidosis, particularly in its extra-pulmonary form. These data support the need for good quality therapeutic trials to validate the use of hydroxychloroquine in this specific indication.
Identifiants
pubmed: 35660263
pii: S0248-8663(22)00453-2
doi: 10.1016/j.revmed.2022.04.030
pii:
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Steroids
0
Hydroxychloroquine
4QWG6N8QKH
Types de publication
Journal Article
Review
Langues
fre
Sous-ensembles de citation
IM
Pagination
406-411Informations de copyright
Copyright © 2022 Société Nationale Française de Médecine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.